Acorda Rebuffed by U.S. Supreme Court Over Ampyra Patents

Bookmark
(Bloomberg) -- The U.S. Supreme Court rebuffed Acorda Therapeutics Inc.’s bid to revive patents on its top-selling multiple sclerosis drug Ampyra.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.